Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Fennec Pharmaceuticals (FENC) over the last 8 years, with Q3 2025 value amounting to $5.9 million.

  • Fennec Pharmaceuticals' Other Operating Expenses fell 147.7% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 1125.75%. This contributed to the annual value of $21.6 million for FY2024, which is 6148.56% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Other Operating Expenses is $5.9 million, which was down 147.7% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Other Operating Expenses peaked at $6.0 million during Q3 2024, and registered a low of -$10.0 million during Q2 2022.
  • For the 4-year period, Fennec Pharmaceuticals' Other Operating Expenses averaged around $3.3 million, with its median value being $4.6 million (2023).
  • Per our database at Business Quant, Fennec Pharmaceuticals' Other Operating Expenses soared by 12483.53% in 2023 and then crashed by 4235.11% in 2025.
  • Fennec Pharmaceuticals' Other Operating Expenses (Quarter) stood at -$10.0 million in 2022, then surged by 145.45% to $4.6 million in 2023, then increased by 1.32% to $4.6 million in 2024, then increased by 27.25% to $5.9 million in 2025.
  • Its Other Operating Expenses was $5.9 million in Q3 2025, compared to $5.3 million in Q2 2025 and $3.3 million in Q1 2025.